Silence Therapeutics (SLN)
(Delayed Data from NSDQ)
$21.30 USD
-0.12 (-0.56%)
Updated May 2, 2024 04:00 PM ET
After-Market: $21.24 -0.06 (-0.28%) 4:52 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Silence Therapeutics PLC Sponsored ADR (SLN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$57.25 | $75.00 | $42.00 | 167.27% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for Silence Therapeutics PLC Sponsored ADR comes to $57.25. The forecasts range from a low of $42.00 to a high of $75.00. The average price target represents an increase of 167.27% from the last closing price of $21.42.
Analyst Price Targets (4 )
Broker Rating
Silence Therapeutics PLC Sponsored ADR currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by five brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on five recommendations.
Of the five recommendations deriving the current ABR, five are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/14/2024 | Chardan Capital Markets | Keay T Nakae | Strong Buy | Strong Buy |
3/13/2024 | H.C. Wainwright & Co. | Patrick Trucchio | Strong Buy | Strong Buy |
2/1/2024 | William Blair | Myles R Minter | Strong Buy | Strong Buy |
1/31/2024 | BMO Capital Markets | Kostas Biliouris | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 5 |
Average Target Price | $57.25 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 96 of 252 |
Current Quarter EPS Est: | -0.23 |